BIRC8

Across TCGA pan-cancer cohorts, BIRC8 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated BIRC8 data layer compared with 10 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher BIRC8 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated BIRC8 expression acts as an unfavorable survival marker.

BLCA, KIRP, and LGG are the cancer types where BIRC8 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	All	0.131	0.627	<.001	21	view →
KIRP	DFS	Median	All	0.016	0.920	<.001	12	view →
LGG	DFS	Median	All	0.165	0.834	<.001	10	view →
LUAD	DFS	Median	IV	0.342	0.893	<.001	10	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LIHC	DFS	Median	II,III,IV	0.111	0.422	.017	6	view →
SKCM	DFS	Median	All	0.542	0.743	.041	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

BIRC8–BLCA (DFS)

Open the BLCA breakdown →